26 May 2013
Keywords: fda, issues, warning, over-use, esas, amgen, hardest
Article | 19 March 2007
The US Food and Drug Administration has issued a public health advisory outlining strengthened product labeling on erythropoeisis-stimulating
agents (ESAs), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 March 2007
24 May 2013
© 2013 thepharmaletter.com